Cytosorbents Corporation (CTSO) 10-Year Financial Performance & Capital Metrics

CTSO • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Show more

Revenue $36M +14.5%
EBITDA -$15M +49.2%
Net Income -$21M +29.2%
EPS (Diluted) -0.38 +41.5%
Gross Margin 70.59%
EBITDA Margin -42.75% +55.6%
Operating Margin -47.16% +54.1%
Net Margin -58.21% +38.1%
ROE -120.52% -20.8%
ROIC -40.5% +50.2%
Debt/Equity 2.42 +207.7%
Interest Coverage -12.00 +94.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 21.9% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.46%

5Y9.35%

3Y-3.9%

TTM9.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM62.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM66.14%

ROCE

10Y Avg-81.94%

5Y Avg-42.52%

3Y Avg-54.01%

Latest-44.02%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.06M	8.21M	13.38M	20.25M	22.77M	39.45M	40.11M	34.69M	31.08M	35.59M
Revenue Growth %	0.29%	1.02%	0.63%	0.51%	0.12%	0.73%	0.02%	-0.14%	-0.1%	0.15%
Cost of Goods Sold+	2.21M	3.95M	5.52M	7.49M	7.36M	11.05M	11.05M	13.96M	9.13M	10.47M
COGS % of Revenue	0.55%	0.48%	0.41%	0.37%	0.32%	0.28%	0.28%	0.4%	0.29%	0.29%
Gross Profit+	1.84M	4.25M	7.86M	12.76M	15.4M	28.4M	29.06M	20.73M	21.95M	25.13M
Gross Margin %	0.45%	0.52%	0.59%	0.63%	0.68%	0.72%	0.72%	0.6%	0.71%	0.71%
Gross Profit Growth %	0.82%	1.31%	0.85%	0.62%	0.21%	0.84%	0.02%	-0.29%	0.06%	0.14%
Operating Expenses+	11.15M	15.74M	17.71M	28.35M	34.38M	38.77M	51.81M	52.25M	53.9M	41.91M
OpEx % of Revenue	2.75%	1.92%	1.32%	1.4%	1.51%	0.98%	1.29%	1.51%	1.73%	1.18%
Selling, General & Admin	8.01M	12.28M	15.43M	22.88M	24.47M	31.51M	38.48M	2.79M	38.31M	0
SG&A % of Revenue	1.98%	1.5%	1.15%	1.13%	1.07%	0.8%	0.96%	0.08%	1.23%	-
Research & Development	3.87M	4.78M	4.05M	7.72M	12.09M	8.81M	16.38M	15.12M	15.59M	6.92M
R&D % of Revenue	0.95%	0.58%	0.3%	0.38%	0.53%	0.22%	0.41%	0.44%	0.5%	0.19%
Other Operating Expenses	-735.86K	-1.32M	-1.77M	-2.25M	-2.18M	-1.55M	-3.06M	34.34M	0	35M
Operating Income+	-9.3M	-11.49M	-9.84M	-15.58M	-18.97M	-10.37M	-22.74M	-31.52M	-31.95M	-16.79M
Operating Margin %	-2.29%	-1.4%	-0.74%	-0.77%	-0.83%	-0.26%	-0.57%	-0.91%	-1.03%	-0.47%
Operating Income Growth %	-0.28%	-0.24%	0.14%	-0.58%	-0.22%	0.45%	-1.19%	-0.39%	-0.01%	0.47%
EBITDA+	-9.19M	-11.33M	-9.62M	-15.19M	-18.39M	-9.71M	-21.62M	-30.64M	-29.93M	-15.22M
EBITDA Margin %	-2.27%	-1.38%	-0.72%	-0.75%	-0.81%	-0.25%	-0.54%	-0.88%	-0.96%	-0.43%
EBITDA Growth %	-0.27%	-0.23%	0.15%	-0.58%	-0.21%	0.47%	-1.23%	-0.42%	0.02%	0.49%
D&A (Non-Cash Add-back)	112.97K	161.61K	218.27K	390.55K	581.53K	660.79K	1.13M	882.62K	2.02M	1.57M
EBIT	-9.3M	-11.85M	-8.39M	-16.37M	-19.32M	-10.37M	-22.74M	-30.89M	-29.9M	-16.79M
Net Interest Income+	9.3K	-231.8K	-749.08K	-1.46M	-1.03M	-1.2M	28.01K	132.6K	-157.89K	-1.4M
Interest Income	18.6K	0	0	0	0	0	28K	133K	0	0
Interest Expense	9.3K	231.8K	749.08K	1.46M	1.03M	1.2M	0	0	157.89K	1.4M
Other Income/Expense	847.32K	-589.88K	705.06K	-2.25M	-1.38M	1.41M	-2.55M	-2.38M	1.89M	-5.62M
Pretax Income+	-8.46M	-12.26M	-9.14M	-17.83M	-20.36M	-8.96M	-25.29M	-33.91M	-30.06M	-22.41M
Pretax Margin %	-2.09%	-1.49%	-0.68%	-0.88%	-0.89%	-0.23%	-0.63%	-0.98%	-0.97%	-0.63%
Income Tax+	-324.61K	-318.55K	-676.74K	-619.55K	-1.09M	-1.13M	-736K	-1.09M	-813.74K	-1.69M
Effective Tax Rate %	0.96%	0.97%	0.93%	0.97%	0.95%	0.87%	0.97%	0.97%	0.97%	0.92%
Net Income+	-8.13M	-11.94M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-29.25M	-20.72M
Net Margin %	-2%	-1.45%	-0.63%	-0.85%	-0.85%	-0.2%	-0.61%	-0.95%	-0.94%	-0.58%
Net Income Growth %	0.13%	-0.47%	0.29%	-1.03%	-0.12%	0.59%	-2.13%	-0.34%	0.11%	0.29%
Net Income (Continuing)	-8.13M	-11.76M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-29.25M	-20.72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.33	-0.47	-0.31	-0.56	-0.60	-0.20	-0.57	-0.75	-0.65	-0.38
EPS Growth %	0.49%	-0.42%	0.34%	-0.81%	-0.07%	0.67%	-1.85%	-0.32%	0.13%	0.42%
EPS (Basic)	-0.33	-0.47	-0.31	-0.56	-0.60	-0.20	-0.57	-0.75	-0.65	-0.38
Diluted Shares Outstanding	24.89M	25.43M	27.61M	30.72M	32.26M	38.82M	43.36M	43.57M	44.66M	54.43M
Basic Shares Outstanding	24.89M	25.43M	27.61M	30.72M	32.26M	38.82M	43.36M	43.57M	44.66M	54.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.86M	7.83M	20.74M	28.26M	20.9M	82.45M	64.3M	33.76M	25.7M	21.6M
Cash & Short-Term Investments	7.51M	5.25M	17.32M	22.37M	12.23M	71.42M	52.14M	22.14M	14.13M	3.28M
Cash Only	5.32M	5.25M	17.32M	22.37M	12.23M	71.42M	52.14M	22.14M	14.13M	3.28M
Short-Term Investments	2.19M	0	0	0	0	0	0	0	0	0
Accounts Receivable	648.87K	1.43M	2.21M	3.94M	4.47M	5.16M	4.52M	5.66M	6.06M	7.32M
Days Sales Outstanding	58.4	63.76	60.17	71.07	71.62	47.73	41.16	59.61	71.12	75.06
Inventory	1.19M	833.98K	795.66K	833.13K	2.11M	2.67M	4.77M	3.46M	3.68M	2.73M
Days Inventory Outstanding	196.42	76.99	52.63	40.6	104.78	88.3	157.47	90.53	147.1	95.29
Other Current Assets	0	0	0	0	-214	0	2.87M	2.49M	1.83M	8.27M
Total Non-Current Assets+	1.39M	1.87M	3.36M	4.48M	6.48M	7.5M	25.22M	29.47M	27.56M	25.77M
Property, Plant & Equipment	557.29K	569.41K	1.4M	1.73M	3M	3.15M	18.57M	23.35M	22.12M	20.51M
Fixed Asset Turnover	7.28x	14.41x	9.54x	11.71x	7.60x	12.53x	2.16x	1.49x	1.41x	1.74x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	771.79K	1.19M	1.84M	2.63M	3.36M	4.22M	4.7M	4.39M	3.91M	3.75M
Long-Term Investments	64.95K	104.91K	123.13K	128.11K	123.48K	125.89K	1.94M	1.73M	1.48M	0
Other Non-Current Assets	64.95K	104.91K	123.13K	0	3.48M	0	0	0	-3.65M	1.51M
Total Assets+	11.25M	9.69M	24.1M	32.75M	27.38M	89.95M	89.52M	63.23M	53.26M	47.37M
Asset Turnover	0.36x	0.85x	0.56x	0.62x	0.83x	0.44x	0.45x	0.55x	0.58x	0.75x
Asset Growth %	0.33%	-0.14%	1.49%	0.36%	-0.16%	2.28%	-0%	-0.29%	-0.16%	-0.11%
Total Current Liabilities+	3.04M	6.09M	7.85M	6.54M	9.94M	10.15M	13.69M	9.71M	14.55M	9.82M
Accounts Payable	684.63K	1.33M	1.24M	1.49M	2.04M	2.47M	2.81M	1.66M	3.8M	3.34M
Days Payables Outstanding	112.94	122.79	82.31	72.41	101.08	81.46	92.68	43.29	151.97	116.45
Short-Term Debt	0	833.33K	4M	666.67K	2.09M	0	570.57K	108.94K	2.5M	0
Deferred Revenue (Current)	30K	1000K	14.75K	0	157.66K	1000K	1000K	1000K	1000K	419.33K
Other Current Liabilities	2.19M	44.88K	1.58M	479.78K	200.84K	0	4.31M	3.55M	3.15M	865.51K
Current Ratio	3.24x	1.29x	2.64x	4.32x	2.10x	8.12x	4.70x	3.48x	1.77x	2.20x
Quick Ratio	2.85x	1.15x	2.54x	4.20x	1.89x	7.86x	4.35x	3.12x	1.51x	1.92x
Cash Conversion Cycle	141.88	17.96	30.48	39.26	75.33	54.57	105.95	106.85	66.24	53.89
Total Non-Current Liabilities+	714.63K	4.08M	5.99M	9.27M	14.03M	581.64K	13.25M	18.14M	15.44M	26.44M
Long-Term Debt	0	4.08M	5.99M	9.27M	13.39M	0	0	5M	2.54M	14M
Capital Lease Obligations	0	0	0	1.07M	642.68K	581.64K	13.25M	13.14M	12.9M	12.44M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	3.71M	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.04M	10.17M	13.84M	15.81M	23.96M	10.73M	26.94M	27.86M	29.99M	36.26M
Total Debt+	0	4.91M	9.99M	9.94M	16.55M	1.03M	13.82M	18.25M	18.31M	26.89M
Net Debt	-5.32M	-333.53K	-7.33M	-12.43M	4.32M	-70.39M	-38.32M	-3.89M	4.18M	23.61M
Debt / Equity	-	-	0.97x	0.59x	4.84x	0.01x	0.22x	0.52x	0.79x	2.42x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1000.29x	-49.58x	-13.14x	-10.67x	-18.36x	-8.63x	-	-	-202.35x	-12.00x
Total Equity+	8.21M	-474.09K	10.26M	16.93M	3.42M	79.22M	62.58M	35.37M	23.28M	11.11M
Equity Growth %	1.07%	-1.06%	22.65%	0.65%	-0.8%	22.18%	-0.21%	-0.43%	-0.34%	-0.52%
Book Value per Share	0.33	-0.02	0.37	0.55	0.11	2.04	1.44	0.81	0.52	0.20
Total Shareholders' Equity	8.21M	-474.09K	10.26M	16.93M	3.42M	79.22M	62.58M	35.37M	23.28M	11.11M
Common Stock	25.4K	25.48K	28.97K	31.77K	32.62K	43.22K	43.48K	43.63K	54.24K	54.83K
Retained Earnings	-132.53M	-144.46M	-152.31M	-169.52M	-188.79M	-196.63M	-221.19M	-254M	-282.51M	-304.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	584.32K	898.68K	-360.99K	288.18K	525.98K	-1.73M	525.59K	2.33M	529.32K	4.25M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.01M	-6.73M	-6.46M	-10.84M	-16.76M	-5.61M	-14.01M	-28.23M	-21.66M	-14.43M
Operating CF Margin %	-2.22%	-0.82%	-0.48%	-0.54%	-0.74%	-0.14%	-0.35%	-0.81%	-0.7%	-0.41%
Operating CF Growth %	-0.35%	0.25%	0.04%	-0.68%	-0.55%	0.67%	-1.5%	-1.02%	0.23%	0.33%
Net Income	-8.13M	-11.94M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-28.51M	-20.72M
Depreciation & Amortization	112.97K	161.61K	218.27K	390.55K	581.53K	660.79K	1.13M	1.13M	2.03M	1.75M
Stock-Based Compensation	382.28K	2.76M	3.31M	0	2.84M	4.71M	6.2M	3.8M	3.7M	3.76M
Deferred Taxes	386.44K	598.87K	-1.45M	799.51K	422.79K	-2.71M	0	0	0	0
Other Non-Cash Items	-1.35M	30.48K	82.05K	734.04K	115.21K	322.81K	2.58M	3.21M	-1.24M	5.16M
Working Capital Changes	-413.59K	1.66M	-160.6K	-937.77K	-1.45M	-757.87K	641.9K	-3.56M	2.36M	-4.38M
Change in Receivables	131.97K	-889.72K	-649.32K	-1.85M	-642.17K	-326.86K	420.58K	-1.29M	-245.62K	-1.72M
Change in Inventory	-632.53K	340.39K	57.32K	-56.75K	-1.28M	-461.51K	-2.35M	945.35K	-121.04K	500.47K
Change in Payables	-83.17K	2.06M	523.38K	1.7M	470.55K	1.42T	2.43M	-3.25M	1.62M	-1.81M
Cash from Investing+	-890.9K	1.6M	-1.68M	-1.52M	-1.52M	-1.68M	-4.28M	-6.46M	-936.24K	-669.43K
Capital Expenditures	-643.45K	-595.53K	-1.68M	-1.52M	-1.52M	-1.68M	-4.28M	-6.46M	-936.24K	-669.43K
CapEx % of Revenue	0.16%	0.07%	0.13%	0.08%	0.07%	0.04%	0.11%	0.19%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	11.64M	5.06M	20.12M	17.47M	8.18M	66.35M	715.2K	4.96M	14.47M	9.33M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-335.73K	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.12M	64.21K	1.78M	3.34M	2.5M	1.13M	0	0	218.28K	-847.95K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.65M	-7.33M	-8.14M	-12.36M	-18.28M	-7.29M	-18.29M	-34.69M	-22.59M	-14.71M
FCF Margin %	-2.38%	-0.89%	-0.61%	-0.61%	-0.8%	-0.18%	-0.46%	-1%	-0.73%	-0.41%
FCF Growth %	-0.37%	0.24%	-0.11%	-0.52%	-0.48%	0.6%	-1.51%	-0.9%	0.35%	0.35%
FCF per Share	-0.39	-0.29	-0.29	-0.40	-0.57	-0.19	-0.42	-0.80	-0.51	-0.27
FCF Conversion (FCF/Net Income)	1.11x	0.56x	0.76x	0.63x	0.87x	0.72x	0.57x	0.86x	0.74x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-133.6%	-308.64%	-172.87%	-126.56%	-189.32%	-18.97%	-34.64%	-67%	-99.73%	-120.52%
Return on Invested Capital (ROIC)	-429.17%	-826.33%	-694.61%	-314.21%	-232.47%	-93.94%	-103.12%	-84.82%	-81.31%	-40.5%
Gross Margin	45.45%	51.82%	58.76%	63.02%	67.65%	71.99%	72.46%	59.77%	70.62%	70.59%
Net Margin	-200.5%	-145.49%	-63.23%	-84.98%	-84.63%	-19.86%	-61.23%	-94.59%	-94.09%	-58.21%
Debt / Equity	-	-	0.97x	0.59x	4.84x	0.01x	0.22x	0.52x	0.79x	2.42x
Interest Coverage	-1000.29x	-49.58x	-13.14x	-10.67x	-18.36x	-8.63x	-	-	-202.35x	-12.00x
FCF Conversion	1.11x	0.56x	0.76x	0.63x	0.87x	0.72x	0.57x	0.86x	0.74x	0.70x
Revenue Growth	28.96%	102.33%	63.07%	51.34%	12.41%	73.3%	1.66%	-13.51%	-10.39%	14.51%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Grant income	-	-	-	-	-	-	-	5.26M	-
Grant income Growth	-	-	-	-	-	-	-	-	-
Other sales	-	-	-	-	-	-	787.2K	69.69K	-
Other sales Growth	-	-	-	-	-	-	-	-91.15%	-
Cyto Sorb Sales	-	-	-	22.55M	39.34M	40M	-	-	-
Cyto Sorb Sales Growth	-	-	-	-	74.50%	1.66%	-	-	-
Other Sales	-	-	-	220.1K	110.4K	111.87K	-	-	-
Other Sales Growth	-	-	-	-	-49.84%	1.33%	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
All other countries	-	-	-	-	-	17.41M	15.82M	18.05M	22.39M
All other countries Growth	-	-	-	-	-	-	-9.12%	14.08%	24.04%
Germany	-	-	-	-	-	-	-	12.96M	13.05M
Germany Growth	-	-	-	-	-	-	-	-	0.66%
United States	-	-	-	-	-	1.69M	968.95K	5.26M	150.61K
United States Growth	-	-	-	-	-	-	-42.66%	443.31%	-97.14%
All Other Countries	3.22M	-	8.39M	8.15M	17.85M	-	-	-	-
All Other Countries Growth	-	-	-	-2.81%	119.08%	-	-	-	-
U	-	-	-	2.18M	1.34M	-	-	-	-
U Growth	-	-	-	-	-38.58%	-	-	-	-
D	-	-	-	-	-	-	-	-	-
D Growth	-	-	-	-	-	-	-	-	-
UNITED STATES	-	1.77M	95.5K	-	-	-	-	-	-
UNITED STATES Growth	-	-	-94.60%	-	-	-	-	-	-
GERMANY	4.99M	-	-	-	-	-	-	-	-
GERMANY Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cytosorbents Corporation (CTSO) reported $36.1M in revenue for fiscal year 2024. This represents a 99982% increase from $0.0M in 2011.

Cytosorbents Corporation (CTSO) grew revenue by 14.5% over the past year. This is steady growth.

Cytosorbents Corporation (CTSO) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Cytosorbents Corporation (CTSO) has a return on equity (ROE) of -120.5%. Negative ROE indicates the company is unprofitable.

Cytosorbents Corporation (CTSO) had negative free cash flow of $10.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cytosorbents Corporation (CTSO) 10-Year Financial Performance & Capital Metrics

CTSO • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

Revenue $36M +14.5%
EBITDA -$15M +49.2%
Net Income -$21M +29.2%
EPS (Diluted) -0.38 +41.5%
Gross Margin 70.59%
EBITDA Margin -42.75% +55.6%
Operating Margin -47.16% +54.1%
Net Margin -58.21% +38.1%
ROE -120.52% -20.8%
ROIC -40.5% +50.2%
Debt/Equity 2.42 +207.7%
Interest Coverage -12.00 +94.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗High debt to equity ratio of 2.4x
✗Negative free cash flow
✗Weak momentum: RS Rating 18 (bottom 18%)
✗Shares diluted 21.9% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y27.46%

5Y9.35%

3Y-3.9%

TTM9.64%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM62.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM66.14%

ROCE

10Y Avg-81.94%

5Y Avg-42.52%

3Y Avg-54.01%

Latest-44.02%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	45.91M	1.25	2.55	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.29M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.64M	2.71	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	27.38M	3.35	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.59M	1.46	-0.11	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	23.21M	1.89	-0.16	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.48M	2.86	-0.27			-380.42%	0.30
TELATELA Bio, Inc.	44.09M	0.99	-0.74	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.06M	8.21M	13.38M	20.25M	22.77M	39.45M	40.11M	34.69M	31.08M	35.59M
Revenue Growth %	0.29%	1.02%	0.63%	0.51%	0.12%	0.73%	0.02%	-0.14%	-0.1%	0.15%
Cost of Goods Sold+	2.21M	3.95M	5.52M	7.49M	7.36M	11.05M	11.05M	13.96M	9.13M	10.47M
COGS % of Revenue	0.55%	0.48%	0.41%	0.37%	0.32%	0.28%	0.28%	0.4%	0.29%	0.29%
Gross Profit+	1.84M	4.25M	7.86M	12.76M	15.4M	28.4M	29.06M	20.73M	21.95M	25.13M
Gross Margin %	0.45%	0.52%	0.59%	0.63%	0.68%	0.72%	0.72%	0.6%	0.71%	0.71%
Gross Profit Growth %	0.82%	1.31%	0.85%	0.62%	0.21%	0.84%	0.02%	-0.29%	0.06%	0.14%
Operating Expenses+	11.15M	15.74M	17.71M	28.35M	34.38M	38.77M	51.81M	52.25M	53.9M	41.91M
OpEx % of Revenue	2.75%	1.92%	1.32%	1.4%	1.51%	0.98%	1.29%	1.51%	1.73%	1.18%
Selling, General & Admin	8.01M	12.28M	15.43M	22.88M	24.47M	31.51M	38.48M	2.79M	38.31M	0
SG&A % of Revenue	1.98%	1.5%	1.15%	1.13%	1.07%	0.8%	0.96%	0.08%	1.23%	-
Research & Development	3.87M	4.78M	4.05M	7.72M	12.09M	8.81M	16.38M	15.12M	15.59M	6.92M
R&D % of Revenue	0.95%	0.58%	0.3%	0.38%	0.53%	0.22%	0.41%	0.44%	0.5%	0.19%
Other Operating Expenses	-735.86K	-1.32M	-1.77M	-2.25M	-2.18M	-1.55M	-3.06M	34.34M	0	35M
Operating Income+	-9.3M	-11.49M	-9.84M	-15.58M	-18.97M	-10.37M	-22.74M	-31.52M	-31.95M	-16.79M
Operating Margin %	-2.29%	-1.4%	-0.74%	-0.77%	-0.83%	-0.26%	-0.57%	-0.91%	-1.03%	-0.47%
Operating Income Growth %	-0.28%	-0.24%	0.14%	-0.58%	-0.22%	0.45%	-1.19%	-0.39%	-0.01%	0.47%
EBITDA+	-9.19M	-11.33M	-9.62M	-15.19M	-18.39M	-9.71M	-21.62M	-30.64M	-29.93M	-15.22M
EBITDA Margin %	-2.27%	-1.38%	-0.72%	-0.75%	-0.81%	-0.25%	-0.54%	-0.88%	-0.96%	-0.43%
EBITDA Growth %	-0.27%	-0.23%	0.15%	-0.58%	-0.21%	0.47%	-1.23%	-0.42%	0.02%	0.49%
D&A (Non-Cash Add-back)	112.97K	161.61K	218.27K	390.55K	581.53K	660.79K	1.13M	882.62K	2.02M	1.57M
EBIT	-9.3M	-11.85M	-8.39M	-16.37M	-19.32M	-10.37M	-22.74M	-30.89M	-29.9M	-16.79M
Net Interest Income+	9.3K	-231.8K	-749.08K	-1.46M	-1.03M	-1.2M	28.01K	132.6K	-157.89K	-1.4M
Interest Income	18.6K	0	0	0	0	0	28K	133K	0	0
Interest Expense	9.3K	231.8K	749.08K	1.46M	1.03M	1.2M	0	0	157.89K	1.4M
Other Income/Expense	847.32K	-589.88K	705.06K	-2.25M	-1.38M	1.41M	-2.55M	-2.38M	1.89M	-5.62M
Pretax Income+	-8.46M	-12.26M	-9.14M	-17.83M	-20.36M	-8.96M	-25.29M	-33.91M	-30.06M	-22.41M
Pretax Margin %	-2.09%	-1.49%	-0.68%	-0.88%	-0.89%	-0.23%	-0.63%	-0.98%	-0.97%	-0.63%
Income Tax+	-324.61K	-318.55K	-676.74K	-619.55K	-1.09M	-1.13M	-736K	-1.09M	-813.74K	-1.69M
Effective Tax Rate %	0.96%	0.97%	0.93%	0.97%	0.95%	0.87%	0.97%	0.97%	0.97%	0.92%
Net Income+	-8.13M	-11.94M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-29.25M	-20.72M
Net Margin %	-2%	-1.45%	-0.63%	-0.85%	-0.85%	-0.2%	-0.61%	-0.95%	-0.94%	-0.58%
Net Income Growth %	0.13%	-0.47%	0.29%	-1.03%	-0.12%	0.59%	-2.13%	-0.34%	0.11%	0.29%
Net Income (Continuing)	-8.13M	-11.76M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-29.25M	-20.72M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.33	-0.47	-0.31	-0.56	-0.60	-0.20	-0.57	-0.75	-0.65	-0.38
EPS Growth %	0.49%	-0.42%	0.34%	-0.81%	-0.07%	0.67%	-1.85%	-0.32%	0.13%	0.42%
EPS (Basic)	-0.33	-0.47	-0.31	-0.56	-0.60	-0.20	-0.57	-0.75	-0.65	-0.38
Diluted Shares Outstanding	24.89M	25.43M	27.61M	30.72M	32.26M	38.82M	43.36M	43.57M	44.66M	54.43M
Basic Shares Outstanding	24.89M	25.43M	27.61M	30.72M	32.26M	38.82M	43.36M	43.57M	44.66M	54.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.86M	7.83M	20.74M	28.26M	20.9M	82.45M	64.3M	33.76M	25.7M	21.6M
Cash & Short-Term Investments	7.51M	5.25M	17.32M	22.37M	12.23M	71.42M	52.14M	22.14M	14.13M	3.28M
Cash Only	5.32M	5.25M	17.32M	22.37M	12.23M	71.42M	52.14M	22.14M	14.13M	3.28M
Short-Term Investments	2.19M	0	0	0	0	0	0	0	0	0
Accounts Receivable	648.87K	1.43M	2.21M	3.94M	4.47M	5.16M	4.52M	5.66M	6.06M	7.32M
Days Sales Outstanding	58.4	63.76	60.17	71.07	71.62	47.73	41.16	59.61	71.12	75.06
Inventory	1.19M	833.98K	795.66K	833.13K	2.11M	2.67M	4.77M	3.46M	3.68M	2.73M
Days Inventory Outstanding	196.42	76.99	52.63	40.6	104.78	88.3	157.47	90.53	147.1	95.29
Other Current Assets	0	0	0	0	-214	0	2.87M	2.49M	1.83M	8.27M
Total Non-Current Assets+	1.39M	1.87M	3.36M	4.48M	6.48M	7.5M	25.22M	29.47M	27.56M	25.77M
Property, Plant & Equipment	557.29K	569.41K	1.4M	1.73M	3M	3.15M	18.57M	23.35M	22.12M	20.51M
Fixed Asset Turnover	7.28x	14.41x	9.54x	11.71x	7.60x	12.53x	2.16x	1.49x	1.41x	1.74x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	771.79K	1.19M	1.84M	2.63M	3.36M	4.22M	4.7M	4.39M	3.91M	3.75M
Long-Term Investments	64.95K	104.91K	123.13K	128.11K	123.48K	125.89K	1.94M	1.73M	1.48M	0
Other Non-Current Assets	64.95K	104.91K	123.13K	0	3.48M	0	0	0	-3.65M	1.51M
Total Assets+	11.25M	9.69M	24.1M	32.75M	27.38M	89.95M	89.52M	63.23M	53.26M	47.37M
Asset Turnover	0.36x	0.85x	0.56x	0.62x	0.83x	0.44x	0.45x	0.55x	0.58x	0.75x
Asset Growth %	0.33%	-0.14%	1.49%	0.36%	-0.16%	2.28%	-0%	-0.29%	-0.16%	-0.11%
Total Current Liabilities+	3.04M	6.09M	7.85M	6.54M	9.94M	10.15M	13.69M	9.71M	14.55M	9.82M
Accounts Payable	684.63K	1.33M	1.24M	1.49M	2.04M	2.47M	2.81M	1.66M	3.8M	3.34M
Days Payables Outstanding	112.94	122.79	82.31	72.41	101.08	81.46	92.68	43.29	151.97	116.45
Short-Term Debt	0	833.33K	4M	666.67K	2.09M	0	570.57K	108.94K	2.5M	0
Deferred Revenue (Current)	30K	1000K	14.75K	0	157.66K	1000K	1000K	1000K	1000K	419.33K
Other Current Liabilities	2.19M	44.88K	1.58M	479.78K	200.84K	0	4.31M	3.55M	3.15M	865.51K
Current Ratio	3.24x	1.29x	2.64x	4.32x	2.10x	8.12x	4.70x	3.48x	1.77x	2.20x
Quick Ratio	2.85x	1.15x	2.54x	4.20x	1.89x	7.86x	4.35x	3.12x	1.51x	1.92x
Cash Conversion Cycle	141.88	17.96	30.48	39.26	75.33	54.57	105.95	106.85	66.24	53.89
Total Non-Current Liabilities+	714.63K	4.08M	5.99M	9.27M	14.03M	581.64K	13.25M	18.14M	15.44M	26.44M
Long-Term Debt	0	4.08M	5.99M	9.27M	13.39M	0	0	5M	2.54M	14M
Capital Lease Obligations	0	0	0	1.07M	642.68K	581.64K	13.25M	13.14M	12.9M	12.44M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	3.71M	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	3.04M	10.17M	13.84M	15.81M	23.96M	10.73M	26.94M	27.86M	29.99M	36.26M
Total Debt+	0	4.91M	9.99M	9.94M	16.55M	1.03M	13.82M	18.25M	18.31M	26.89M
Net Debt	-5.32M	-333.53K	-7.33M	-12.43M	4.32M	-70.39M	-38.32M	-3.89M	4.18M	23.61M
Debt / Equity	-	-	0.97x	0.59x	4.84x	0.01x	0.22x	0.52x	0.79x	2.42x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-1000.29x	-49.58x	-13.14x	-10.67x	-18.36x	-8.63x	-	-	-202.35x	-12.00x
Total Equity+	8.21M	-474.09K	10.26M	16.93M	3.42M	79.22M	62.58M	35.37M	23.28M	11.11M
Equity Growth %	1.07%	-1.06%	22.65%	0.65%	-0.8%	22.18%	-0.21%	-0.43%	-0.34%	-0.52%
Book Value per Share	0.33	-0.02	0.37	0.55	0.11	2.04	1.44	0.81	0.52	0.20
Total Shareholders' Equity	8.21M	-474.09K	10.26M	16.93M	3.42M	79.22M	62.58M	35.37M	23.28M	11.11M
Common Stock	25.4K	25.48K	28.97K	31.77K	32.62K	43.22K	43.48K	43.63K	54.24K	54.83K
Retained Earnings	-132.53M	-144.46M	-152.31M	-169.52M	-188.79M	-196.63M	-221.19M	-254M	-282.51M	-304.01M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	584.32K	898.68K	-360.99K	288.18K	525.98K	-1.73M	525.59K	2.33M	529.32K	4.25M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.01M	-6.73M	-6.46M	-10.84M	-16.76M	-5.61M	-14.01M	-28.23M	-21.66M	-14.43M
Operating CF Margin %	-2.22%	-0.82%	-0.48%	-0.54%	-0.74%	-0.14%	-0.35%	-0.81%	-0.7%	-0.41%
Operating CF Growth %	-0.35%	0.25%	0.04%	-0.68%	-0.55%	0.67%	-1.5%	-1.02%	0.23%	0.33%
Net Income	-8.13M	-11.94M	-8.46M	-17.21M	-19.27M	-7.84M	-24.56M	-32.81M	-28.51M	-20.72M
Depreciation & Amortization	112.97K	161.61K	218.27K	390.55K	581.53K	660.79K	1.13M	1.13M	2.03M	1.75M
Stock-Based Compensation	382.28K	2.76M	3.31M	0	2.84M	4.71M	6.2M	3.8M	3.7M	3.76M
Deferred Taxes	386.44K	598.87K	-1.45M	799.51K	422.79K	-2.71M	0	0	0	0
Other Non-Cash Items	-1.35M	30.48K	82.05K	734.04K	115.21K	322.81K	2.58M	3.21M	-1.24M	5.16M
Working Capital Changes	-413.59K	1.66M	-160.6K	-937.77K	-1.45M	-757.87K	641.9K	-3.56M	2.36M	-4.38M
Change in Receivables	131.97K	-889.72K	-649.32K	-1.85M	-642.17K	-326.86K	420.58K	-1.29M	-245.62K	-1.72M
Change in Inventory	-632.53K	340.39K	57.32K	-56.75K	-1.28M	-461.51K	-2.35M	945.35K	-121.04K	500.47K
Change in Payables	-83.17K	2.06M	523.38K	1.7M	470.55K	1.42T	2.43M	-3.25M	1.62M	-1.81M
Cash from Investing+	-890.9K	1.6M	-1.68M	-1.52M	-1.52M	-1.68M	-4.28M	-6.46M	-936.24K	-669.43K
Capital Expenditures	-643.45K	-595.53K	-1.68M	-1.52M	-1.52M	-1.68M	-4.28M	-6.46M	-936.24K	-669.43K
CapEx % of Revenue	0.16%	0.07%	0.13%	0.08%	0.07%	0.04%	0.11%	0.19%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	11.64M	5.06M	20.12M	17.47M	8.18M	66.35M	715.2K	4.96M	14.47M	9.33M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-335.73K	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.12M	64.21K	1.78M	3.34M	2.5M	1.13M	0	0	218.28K	-847.95K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.65M	-7.33M	-8.14M	-12.36M	-18.28M	-7.29M	-18.29M	-34.69M	-22.59M	-14.71M
FCF Margin %	-2.38%	-0.89%	-0.61%	-0.61%	-0.8%	-0.18%	-0.46%	-1%	-0.73%	-0.41%
FCF Growth %	-0.37%	0.24%	-0.11%	-0.52%	-0.48%	0.6%	-1.51%	-0.9%	0.35%	0.35%
FCF per Share	-0.39	-0.29	-0.29	-0.40	-0.57	-0.19	-0.42	-0.80	-0.51	-0.27
FCF Conversion (FCF/Net Income)	1.11x	0.56x	0.76x	0.63x	0.87x	0.72x	0.57x	0.86x	0.74x	0.70x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-133.6%	-308.64%	-172.87%	-126.56%	-189.32%	-18.97%	-34.64%	-67%	-99.73%	-120.52%
Return on Invested Capital (ROIC)	-429.17%	-826.33%	-694.61%	-314.21%	-232.47%	-93.94%	-103.12%	-84.82%	-81.31%	-40.5%
Gross Margin	45.45%	51.82%	58.76%	63.02%	67.65%	71.99%	72.46%	59.77%	70.62%	70.59%
Net Margin	-200.5%	-145.49%	-63.23%	-84.98%	-84.63%	-19.86%	-61.23%	-94.59%	-94.09%	-58.21%
Debt / Equity	-	-	0.97x	0.59x	4.84x	0.01x	0.22x	0.52x	0.79x	2.42x
Interest Coverage	-1000.29x	-49.58x	-13.14x	-10.67x	-18.36x	-8.63x	-	-	-202.35x	-12.00x
FCF Conversion	1.11x	0.56x	0.76x	0.63x	0.87x	0.72x	0.57x	0.86x	0.74x	0.70x
Revenue Growth	28.96%	102.33%	63.07%	51.34%	12.41%	73.3%	1.66%	-13.51%	-10.39%	14.51%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Grant income	-	-	-	-	-	-	-	5.26M	-
Grant income Growth	-	-	-	-	-	-	-	-	-
Other sales	-	-	-	-	-	-	787.2K	69.69K	-
Other sales Growth	-	-	-	-	-	-	-	-91.15%	-
Cyto Sorb Sales	-	-	-	22.55M	39.34M	40M	-	-	-
Cyto Sorb Sales Growth	-	-	-	-	74.50%	1.66%	-	-	-
Other Sales	-	-	-	220.1K	110.4K	111.87K	-	-	-
Other Sales Growth	-	-	-	-	-49.84%	1.33%	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
All other countries	-	-	-	-	-	17.41M	15.82M	18.05M	22.39M
All other countries Growth	-	-	-	-	-	-	-9.12%	14.08%	24.04%
Germany	-	-	-	-	-	-	-	12.96M	13.05M
Germany Growth	-	-	-	-	-	-	-	-	0.66%
United States	-	-	-	-	-	1.69M	968.95K	5.26M	150.61K
United States Growth	-	-	-	-	-	-	-42.66%	443.31%	-97.14%
All Other Countries	3.22M	-	8.39M	8.15M	17.85M	-	-	-	-
All Other Countries Growth	-	-	-	-2.81%	119.08%	-	-	-	-
U	-	-	-	2.18M	1.34M	-	-	-	-
U Growth	-	-	-	-	-38.58%	-	-	-	-
D	-	-	-	-	-	-	-	-	-
D Growth	-	-	-	-	-	-	-	-	-
UNITED STATES	-	1.77M	95.5K	-	-	-	-	-	-
UNITED STATES Growth	-	-	-94.60%	-	-	-	-	-	-
GERMANY	4.99M	-	-	-	-	-	-	-	-
GERMANY Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Cytosorbents Corporation (CTSO) reported $36.1M in revenue for fiscal year 2024. This represents a 99982% increase from $0.0M in 2011.

Cytosorbents Corporation (CTSO) grew revenue by 14.5% over the past year. This is steady growth.

Cytosorbents Corporation (CTSO) reported a net loss of $9.7M for fiscal year 2024.

Dividend & Returns

Cytosorbents Corporation (CTSO) has a return on equity (ROE) of -120.5%. Negative ROE indicates the company is unprofitable.

Cytosorbents Corporation (CTSO) had negative free cash flow of $10.3M in fiscal year 2024, likely due to heavy capital investments.